Financing translation: Analysis of the NCATS rare-diseases portfolio

Science Translational Medicine

Volumn 7, Issue 276, 2015, Pages

  Fagnan, David E ^a,b,f   Yang, N Nora ^c,f   McKew, John C ^c   Lo, Andrew W ^a,b,d,e  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Department of Electrical Engineering and Computer Science   (United States)

^e LLC   (United States)

^f aTyr Pharma   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; DECISION MAKING; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; FINANCIAL DEFICIT; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH PROGRAM; HUMAN; INVESTMENT; MEDICAL RESEARCH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC-PRIVATE PARTNERSHIP; RARE DISEASE; SENSITIVITY ANALYSIS; SHORT SURVEY; SIMULATION; CALIBRATION; ECONOMICS; HEALTH CARE FINANCING; TRANSLATIONAL RESEARCH;

CALIBRATION; HEALTHCARE FINANCING; HUMANS; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84923902179     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa2360     Document Type: Short Survey

References (12)

1. The Global Genes Project, "The Global Genes Project" (2014); https://globalgenes.org/rare-diseases-factsstatistics.
2. National Organization of Rare Diseases, 4 January 2013; www.rarediseases.org/news-events/news/30-years-oda.
3. FDA, Search orphan drug designations and approvals; www.accessdata.fda.gov/scripts/opdlisting/oopd.
4. D. E. Fagnan, A. A. Gromatzky, R. M. Stein, J. M. Fernandez, A. W. Lo, Financing drug discovery for orphan diseases. Drug Discov. Today 19, 533-538 (2014).
5. Scientific Management Review Board, Report on Translational Medicine and Therapeutics (NIH, Bethesda, 2010).
6. M. Cha, B. Rifai, P. Sarraf, Pharmaceutical forecasting: Throwing darts? Nat. Rev. Drug Discov. 12, 737-738 (2013).
7. DBRS, Inc., Rating Global Film Rights Securitizations (DBRS, New York, 2010).
8. J.-M. Fernandez, R. M. Stein, A. W. Lo, Commercializing biomedical research through securitization techniques. Nat. Biotechnol. 30, 964-975 (2012).
9. D. E. Fagnan, J. M. Fernandez, A. W. Lo, R. M. Stein, Can financial engineering cure cancer? Am. Econ. Rev. 103, 406-411 (2013).
10. A. W. Lo, S. V. Naraharisetti, New financing methods in the biopharma industry: A case study of Royalty Pharma, Inc. J. Invest. Manag. 12, 3-19 (2014).
11. S. Ro, CHART: 27 years of failed Wall Street earnings forecasts, 18 December 2012; www.businessinsider.com/gerard-minack-forecasting-earnings-2012-12.
12. J. Y. Campbell, A. W. Lo, A. C. MacKinlay, The Econometrics of Financial Markets (Princeton Univ. Press, Princeton, NJ, 1996).